Jeffery A. Smisek - 22 Nov 2023 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Director
Signature
By: /s/ Jeffery A. Smisek
Issuer symbol
FNCH
Transactions as of
22 Nov 2023
Net transactions value
-$5,351
Form type
4
Filing time
27 Nov 2023, 16:54:09 UTC
Previous filing
09 Jun 2023
Next filing
29 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FNCH Common Stock Sale $5,351 -1,470 -18% $3.64 6,642 22 Nov 2023 Direct F1, F2
holding FNCH Common Stock 40,260 22 Nov 2023 See footnote F3
holding FNCH Common Stock 8,112 22 Nov 2023 By spouse F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted-average price of shares sold by the broker on behalf of the Reporting Person. The broker sold, in the aggregate on behalf of such Reporting Person, 1,470 shares in transactions ranging from $3.63 to $3.67 with a weighted-average price of $3.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Includes shares previously held indirectly by Flight Partners Management LLC ("Flight Partners Capital") and are now held directly. The Reporting Person is the president of Flight Partners Capital.
F3 The securities are held by Flight Partners Capital.
F4 Includes shares previously held indirectly by Flight Partners Capital and are now held by the Reporting Person's spouse.